Table 3. Immune status of pregnant women with oncological diseases, healthy pregnant women, and their newborns (M±SD)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Women | | | | Newborns | | | |
| Breast cancer with chemotherapy (n=9) | Hemoblastoses with chemotherapy (n=9) | Hemoblastoses with IFN therapy (n=8) | Control group (n=20) | Breast cancer with chemotherapy (n=11) | Hemoblastoses with chemotherapy (n=8) | Hemoblastoses with IFN therapy (n=8) | Control group (n=26) |
| CD3+ (%) | 74,9±14,6 | 62,3±15,7 | **61,6±12,1** \* | 70,0±6,7 | 66,1±8,6 | 67,9±16,9 | 66,3±13,8 | 64,2±12,1 |
| CD3+CD4+ (%) | 36,9±11,8 | 34,8±11,9 | **31,4±7,0** \* | 40,7±6,1 | 45,6±7,1 | 49,3±12,3 | 46,0±13,4 | 46,0±12,2 |
| CD3+CD8+ (%) | 35,1±10,7 \* | 27,5±7,8 | 27,5±7,0 | 26,4±6,9 | 21,1±5,7 | 19,2±6,7 | 20,3±3,1 | 20,2±4,7 |
| CD3+CD4+/CD3+CD8+ | 1,2±0,7 | 1,3±0,6 | **1,2±0,3** \* | 1,7±0,6 | 2,3±0,6 | 2,7±0,5 | 2,3±0,7 | 2,4±0,6 |
| CD19+ (%) | **1,9±1,6** \* | 4,3±3,8 | 16,3±15,2 | 7,5±3,2 | **11,2±5,6** \* | **7,7±5,1** \* | 13,8±5,1 | 15,4±6,1 |
| CD19+CD5+ (%) | 0,4±0,6 | 0,5±0,4 | 1,8±1,9 | 0,6±0,5 | **6,2±4,8** \* | **3,8±3,5** \* | 8,8±5,6 | 7,0±3,7 |
| CD16+CD56+ (%) | 11,1±5,9 | 15,8±14,2 | 13,4±8,0 | 15,6±6,7 | 18,5±11,0 | 21,5±12,0 | 17,4±10,4 | 17,7±9,2 |
| CD3+HLA-DR+ (%) | **13,8±6,8** \* | 12,7±11,7 | 9,7±6,3 | 6,2±2,8 | 0,5±0,4 | 0,4±0,4 | 0,4±0,2 | 0,4±0,2 |
| CD95+ (%) | **53,5±16,4** \* | **50,1±14,5** \* | 46,5±24,9 | 40,6±9,3 | 7,6±10,3 | 3,5±1,3 | 3,6±2,4 | 3,2±2,3 |
| IgG, g/l | 9,34±3,03 | **7,84±0,78** \* | 9,88±2,83 | 11,4±2,8 | **8,41±2,58** \* | 9,54±2,53 | 9,21±3,10 | 10,69±2,77 |
| IgA, g/l | 1,89±1,13 | 1,65±0,66 | 1,85±0,77 | 1,8±0,81 | 0,13±0,28 | **0,02±0,04** \* | 0,09±0,11 | 0,11±0,13 |
| IgM, g/l | 1,93±1,37 | 1,34±0,59 | 1,89±1,26 | 1,9±0,26 | 0,13±0,17 | 0,23±0,24 | 0,27±0,25 | 0,22±0,19 |

\*– p<0,05 comparing to the control group